{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:26:40Z","timestamp":1790612800415,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["20170528"],"award-info":[{"award-number":["20170528"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009824","name":"FSHD Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012644","name":"Friends of FSH Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012644","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009657","name":"FSHD Global Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009657","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000033","name":"Institute of Musculoskeletal Health and Arthritis","doi-asserted-by":"publisher","award":["143251"],"award-info":[{"award-number":["143251"]}],"id":[{"id":"10.13039\/501100000033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Fondation canadienne pour l'innovation","doi-asserted-by":"publisher","award":["30819"],"award-info":[{"award-number":["30819"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020797","name":"NanoMedicines Innovation Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000223","name":"Muscular Dystrophy Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.05.010","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:10:50Z","timestamp":1779808250000},"page":"4856-4878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipid nanoparticle delivery of antisense gapmers attenuates pathology in a mouse model of facioscapulohumeral muscular dystrophy"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-5923","authenticated-orcid":false,"given":"Saeed","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Ying Tung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Zia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji Rowel Q.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Nur Ahad","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umme Sabrina","family":"Haque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Witzigmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Echigoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Bosnakovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kyba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Rutter","family":"Cullis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7316-3546","authenticated-orcid":false,"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.05.010_bib1","series-title":"Facioscapulohumeral Disease","author":"Padberg","year":"1982"},{"key":"10.1016\/j.ymthe.2026.05.010_bib2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1212\/CON.0000000000000801","article-title":"Facioscapulohumeral Muscular Dystrophies","volume":"25","author":"Wagner","year":"2019","journal-title":"Continuum (N. Y)"},{"key":"10.1016\/j.ymthe.2026.05.010_bib3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2026.05.010_bib4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000369343","article-title":"Prevalence of muscular dystrophies: a systematic literature review","volume":"43","author":"Theadom","year":"2014","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.ymthe.2026.05.010_bib5","series-title":"GeneReviews\u00ae [Internet]","article-title":"Facioscapulohumeral muscular dystrophy","author":"Preston","year":"1993"},{"key":"10.1016\/j.ymthe.2026.05.010_bib6","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1177\/22143602241313118","article-title":"Prevalence and incidence rates of 17 neuromuscular disorders: An updated review of the literature","volume":"12","author":"Deenen","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2026.05.010_bib7","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ana.20106","article-title":"Somatic mosaicism in FSHD often goes undetected","volume":"55","author":"Lemmers","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41582-022-00762-2","article-title":"Facioscapulohumeral muscular dystrophy: the road to targeted therapies","volume":"19","author":"Tihaya","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/practneurol-2015-001353","article-title":"What\u2019s in a name? The clinical features of facioscapulohumeral muscular dystrophy","volume":"16","author":"Mul","year":"2016","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mus.20522","article-title":"Facioscapulohumeral muscular dystrophy","volume":"34","author":"Tawil","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2026.05.010_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nmd.2003.07.001","article-title":"Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD)","volume":"14","author":"Tonini","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2026.05.010_bib12","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1212\/WNL.0000000000005915","article-title":"A family-based study into penetrance in facioscapulohumeral muscular dystrophy type 1","volume":"91","author":"Wohlgemuth","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2026.05.010_bib13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/mus.23949","article-title":"Risk of functional impairment in facioscapulohumeral muscular dystrophy","volume":"49","author":"Statland","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2026.05.010_bib14","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1093\/brain\/awab326","article-title":"Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy","volume":"144","author":"Katz","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2026.05.010_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.nmd.2006.06.008","article-title":"Severe phenotype in infantile facioscapulohumeral muscular dystrophy","volume":"16","author":"Klinge","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2026.05.010_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.1994.00540160085011","article-title":"Facioscapulohumeral muscular dystrophy in early childhood","volume":"51","author":"Brouwer","year":"1994","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib17","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.nmd.2017.09.007","article-title":"Early onset facioscapulohumeral dystrophy \u2013 a systematic review using individual patient data","volume":"27","author":"Goselink","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2026.05.010_bib18","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1212\/WNL.51.5.1454","article-title":"Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy","volume":"51","author":"Lafor\u00eat","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2026.05.010_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.668180","article-title":"Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD)","volume":"12","author":"Ducharme-Smith","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.642858","article-title":"Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy","volume":"12","author":"Lim","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13395-025-00388-0","article-title":"DUX4 at 25: how it emerged from \u201cjunk DNA\u201d to become the cause of facioscapulohumeral muscular dystrophy","volume":"15","author":"Belayew","year":"2025","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2026.05.010_bib22","series-title":"Muscle Disease: Pathology and Genetics","first-page":"288","article-title":"Facioscapulohumeral Dystrophy","author":"Flanigan","year":"2013"},{"key":"10.1016\/j.ymthe.2026.05.010_bib23","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science (80-. )"},{"key":"10.1016\/j.ymthe.2026.05.010_bib24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/cge.13726","article-title":"Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy","volume":"97","author":"Greco","year":"2020","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib25","doi-asserted-by":"crossref","first-page":"E2273","DOI":"10.1212\/WNL.0000000000007456","article-title":"FSHD1 and FSHD2 form a disease continuum","volume":"92","author":"Sacconi","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2026.05.010_bib26","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ng.2454","article-title":"Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2","volume":"44","author":"Lemmers","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/ng0992-26","article-title":"Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy","volume":"2","author":"Wijmenga","year":"1992","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/0140-6736(90)92148-B","article-title":"Location of facioscapulohumeral muscular dystrophy gene on chromosome 4","volume":"336","author":"Wijmenga","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2026.05.010_bib29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0888-7543(91)90348-I","article-title":"Mapping of facioscapulohumeral muscular dystrophy gene to chromosome 4q35-qter by multipoint linkage analysis and in situ hybridization","volume":"9","author":"Wijmenga","year":"1991","journal-title":"Genomics"},{"key":"10.1016\/j.ymthe.2026.05.010_bib30","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/hmg\/3.8.1287","article-title":"Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystropothhy","volume":"3","author":"Hewitt","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib31","doi-asserted-by":"crossref","first-page":"e115278","DOI":"10.1371\/journal.pone.0115278","article-title":"DNA methylation analysis of the macrosatellite repeat associated with FSHD muscular dystrophy at single nucleotide level","volume":"9","author":"Huichalaf","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.05.010_bib32","doi-asserted-by":"crossref","first-page":"e0160022","DOI":"10.1371\/journal.pone.0160022","article-title":"Influence of repressive histone and DNA methylation upon D4Z4 transcription in non-myogenic cells","volume":"11","author":"Das","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.05.010_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2012.01647.x","article-title":"DUX4 expression in FSHD muscle cells: How could such a rare protein cause a myopathy?","volume":"17","author":"Tassin","year":"2013","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ymthe.2026.05.010_bib34","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1093\/hmg\/dds284","article-title":"Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis","volume":"21","author":"Jones","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib35","doi-asserted-by":"crossref","first-page":"e1001181","DOI":"10.1371\/journal.pgen.1001181","article-title":"Facioscapulohumeral dystrophy: Incomplete suppression of a retrotransposed gene","volume":"6","author":"Snider","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/ng1262","article-title":"Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy","volume":"35","author":"Van Overveld","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jmedgenet-2015-103436","article-title":"Allele-specific DNA hypomethylation characterises FSHD1 and FSHD2","volume":"53","author":"Calandra","year":"2016","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib38","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1002\/mus.880181309","article-title":"The FSHD-linked locus D4F104S1 (p13E-11) ON 4q35 has a homologue on 10qter","volume":"18","author":"Bakker","year":"1995","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2026.05.010_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000472291","article-title":"Physical mapping evidence for a duplicated region on chromosome 10qter showing high homology with the facioscapulohumeral muscular dystrophy locus on chromosome 4qter","volume":"3","author":"Deidda","year":"1995","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib40","doi-asserted-by":"crossref","first-page":"E1054","DOI":"10.1212\/WNL.0000000000011412","article-title":"CLIA Laboratory Testing for Facioscapulohumeral Dystrophy: A Retrospective Analysis","volume":"96","author":"Rieken","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2026.05.010_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/humu.22792","article-title":"Hemizygosity for SMCHD1 in Facioscapulohumeral Muscular Dystrophy Type 2: Consequences for 18p Deletion Syndrome","volume":"36","author":"Lemmers","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2026.05.010_bib42","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ajhg.2016.03.013","article-title":"Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy","volume":"98","author":"Van Den Boogaard","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib43","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ajhg.2013.08.004","article-title":"The FSHD2 gene SMCHD1 Is a modifier of disease severity in families affected by FSHD1","volume":"93","author":"Sacconi","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib44","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31023","article-title":"NuRD and CAF-1-mediated silencing of the D4Z4 array is modulated by DUX4-induced MBD3L proteins","volume":"7","author":"Campbell","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.ymthe.2026.05.010_bib45","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/ng.3844","article-title":"Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL\/HERVL retrotransposons","volume":"49","author":"Hendrickson","year":"2017","journal-title":"Nat. Genet"},{"key":"10.1016\/j.ymthe.2026.05.010_bib46","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1093\/hmg\/ddu251","article-title":"DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle","volume":"23","author":"Yao","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib47","first-page":"4419","article-title":"Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells","volume":"25","author":"Jagannathan","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib48","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.3390\/ijms21155575","article-title":"Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy","volume":"21","author":"Bittel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.05.010_bib49","doi-asserted-by":"crossref","DOI":"10.1242\/bio.059145","article-title":"Downstream events initiated by expression of FSHD-associated DUX4: Studies of nucleocytoplasmic transport, \u03b3H2AX accumulation, and Bax\/Bak-dependence","volume":"11","author":"Masteika","year":"2022","journal-title":"Biol. Open"},{"key":"10.1016\/j.ymthe.2026.05.010_bib50","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.4747","article-title":"A Biomarker of DUX4 Activity to Evaluate losmapimod Treatment Effect in FSHD Phase 2 Trials (4747)","volume":"94","author":"Ronco","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2026.05.010_bib51","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1093\/hmg\/ddg327","article-title":"Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation","volume":"12","author":"Winokur","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026820","article-title":"The FSHD atrophic myotube phenotype is caused by DUX4 expression","volume":"6","author":"Vanderplanck","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.05.010_bib53","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated knockdown of DUX4 toward facioscapulohumeral muscular dystrophy therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.010_bib54","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddw015","article-title":"Antisense targeting of 3\u2019 end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach","volume":"25","author":"Marsollier","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/genes8030093","article-title":"Antisense oligonucleotides used to target the DUX4 mRNA as therapeutic approaches in faciosscapulohumeral muscular dystrophy (FSHD)","volume":"8","author":"Ansseau","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2026.05.010_bib56","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1073\/pnas.1909649117","article-title":"Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy","volume":"117","author":"Lim","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ymthe.2026.05.010_bib57","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ymthe.2020.10.010","article-title":"DUX4 transcript knockdown with antisense 2\u2032-O-Methoxyethyl gapmers for the treatment of facioscapulohumeral muscular dystrophy","volume":"29","author":"Lim","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.010_bib58","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.omtn.2021.09.010","article-title":"Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy","volume":"26","author":"Bouwman","year":"2021","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.05.010_bib59","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/hmg\/ddab136","article-title":"Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model","volume":"30","author":"Lu-Nguyen","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib60","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3390\/biomedicines11092339","article-title":"A Systemically Administered Unconjugated Antisense Oligonucleotide Targeting DUX4 Improves Muscular Injury and Motor Function in FSHD Model Mice","volume":"11","author":"Kakimoto","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ymthe.2026.05.010_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102791","article-title":"DUX4 reduction and muscle function improvement by subcutaneous delivery of gapmer antisense oligonucleotides","volume":"37","author":"Zhang","year":"2026","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.05.010_bib62","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.3390\/pharmaceutics15041130","article-title":"Enhancing the Effectiveness of Oligonucleotide Therapeutics Using Cell-Penetrating Peptide Conjugation, Chemical Modification, and Carrier-Based Delivery Strategies","volume":"15","author":"Anwar","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2026.05.010_bib63","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.05.010_bib64","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/s41467-017-00730-1","article-title":"Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model","volume":"8","author":"Bosnakovski","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2026.05.010_bib99","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid Nanoparticle Systems for Enabling Gene Therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.010_bib66","doi-asserted-by":"crossref","first-page":"23959","DOI":"10.1039\/D0NR06816K","article-title":"Spontaneous, solvent-free entrapment of siRNA within lipid nanoparticles","volume":"12","author":"Kulkarni","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.ymthe.2026.05.010_bib67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.05.010_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2025.108546","article-title":"Targeted delivery systems of siRNA based on ionizable lipid nanoparticles and cationic polymer vectors","volume":"81","author":"Yao","year":"2025","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ymthe.2026.05.010_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2025.110849","article-title":"Nucleic acid delivery by lipid nanoparticles for organ targeting","volume":"36","author":"Guo","year":"2025","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ymthe.2026.05.010_bib70","doi-asserted-by":"crossref","first-page":"21206","DOI":"10.1021\/acsnano.4c18274","article-title":"Structure and Morphology of Lipid Nanoparticles for Nucleic Acid Drug Delivery: A Review","volume":"19","author":"Udepurkar","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2026.05.010_bib71","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/ijms21030729","article-title":"DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy","volume":"21","author":"Lim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.05.010_bib72","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.05.010_bib93","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.05.010_bib74","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1369\/0022155411410885","article-title":"Biodistribution of Small Interfering RNA at the Organ and Cellular Levels after Lipid Nanoparticle-mediated Delivery","volume":"59","author":"Shi","year":"2011","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.ymthe.2026.05.010_bib73","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1172\/JCI133303","article-title":"Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice","volume":"130","author":"Bosnakovski","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.05.010_bib75","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.05.010_bib76","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymthe.2026.05.010_bib77","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","article-title":"Golodirsen for Duchenne muscular dystrophy","volume":"56","author":"Anwar","year":"2020","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.ymthe.2026.05.010_bib78","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1358\/dot.2019.55.10.3045038","article-title":"Viltolarsen for the treatment of Duchenne muscular dystrophy","volume":"55","author":"Roshmi","year":"2019","journal-title":"Drugs of Today"},{"key":"10.1016\/j.ymthe.2026.05.010_bib79","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1358\/dot.2021.57.12.3352740","article-title":"Casimersen for Duchenne muscular dystrophy","volume":"57","author":"Wilton-Clark","year":"2021","journal-title":"Drugs of Today"},{"key":"10.1016\/j.ymthe.2026.05.010_bib80","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","article-title":"Mipomersen Sodium: First Global Approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.05.010_bib81","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: First Global Approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2026.05.010_bib82","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/nat.2021.0034","article-title":"Altered Biodistribution and Hepatic Safety Profile of a Gapmer Antisense Oligonucleotide Bearing Guanidine-Bridged Nucleic Acids","volume":"32","author":"Sasaki","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2026.05.010_bib83","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13395-017-0130-1","article-title":"Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures","volume":"7","author":"Haynes","year":"2017","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2026.05.010_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008754","article-title":"Single-nucleus RNA-seq identifies divergent populations of FSHD2 myotube nuclei","volume":"16","author":"Jiang","year":"2020","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymthe.2026.05.010_bib85","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.ymthe.2026.05.010_bib86","series-title":"Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers","year":"2005"},{"key":"10.1016\/j.ymthe.2026.05.010_bib87","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1089\/nat.2024.0036","article-title":"An Evaluation of First-in-Human Studies for RNA Oligonucleotides","volume":"34","author":"Stern","year":"2024","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2026.05.010_bib89","series-title":"New Approach Methods (NAMs)","year":"2022"},{"key":"10.1016\/j.ymthe.2026.05.010_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.1086912","article-title":"Editorial: The use of large animal models to improve pre-clinical translational research","volume":"9","author":"Gray","year":"2022","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.ymthe.2026.05.010_bib65","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.3390\/ijms23041983","article-title":"Persistent Fibroadipogenic Progenitor Expansion Following Transient DUX4 Expression Provokes a Profibrotic State in a Mouse Model for FSHD","volume":"23","author":"Bosnakovski","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2026.05.010_bib91","doi-asserted-by":"crossref","DOI":"10.1186\/s13395-020-00227-4","article-title":"Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity","volume":"10","author":"Jones","year":"2020","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2026.05.010_bib92","doi-asserted-by":"crossref","first-page":"e0192657","DOI":"10.1371\/journal.pone.0192657","article-title":"A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy","volume":"13","author":"Jones","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.05.010_bib94","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.05.010_bib95","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2044-5040-3-9","article-title":"Vascular-targeted therapies for Duchenne muscular dystrophy","volume":"3","author":"Ennen","year":"2013","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2026.05.010_bib96","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2026.05.010_bib97","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2012.04.038","article-title":"Macromolecular therapeutics in cancer treatment: The EPR effect and beyond","volume":"164","author":"Maeda","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ymthe.2026.05.010_bib98","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1096\/fj.13-237388","article-title":"Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function","volume":"28","author":"Bibee","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2026.05.010_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.05.010_bib101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41578-025-00831-0","article-title":"High-throughput platforms for machine learning-guided lipid nanoparticle design","volume":"11","author":"Hanna","year":"2026","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ymthe.2026.05.010_bib102","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1039\/D5PM00235D","article-title":"The paradigm shift in therapeutics: a comprehensive review of artificial intelligence in drug delivery systems","volume":"3","author":"Singh","year":"2026","journal-title":"RSC Pharm."},{"key":"10.1016\/j.ymthe.2026.05.010_bib103","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.omtn.2018.02.002","article-title":"Repurposing dantrolene for long-term combination therapy to potentiate antisense-mediated DMD exon skipping in the mdx mouse","volume":"11","author":"Wang","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.05.010_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005054","article-title":"Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy","volume":"4","author":"Kendall","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.05.010_bib105","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1093\/nar\/gkt066","article-title":"The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides","volume":"41","author":"Ming","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.05.010_bib106","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/nar\/gkv060","article-title":"High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides","volume":"43","author":"Yang","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.05.010_bib107","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1021\/acschembio.7b00242","article-title":"A Novel Family of Small Molecules that Enhance the Intracellular Delivery and Pharmacological Effectiveness of Antisense and Splice Switching Oligonucleotides","volume":"12","author":"Wang","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib108","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib109","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2500From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2026.05.010_bib119","doi-asserted-by":"crossref","first-page":"2025076","DOI":"10.20517\/microstructures.2024.172","article-title":"Advances in mRNA-LNP lung-targeted delivery strategies","volume":"5","author":"Liu","year":"2025","journal-title":"Microstructures"},{"key":"10.1016\/j.ymthe.2026.05.010_bib110","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1093\/nar\/gkg599","article-title":"Vienna RNA secondary structure server","volume":"31","author":"Hofacker","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2026.05.010_bib111","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00818163","article-title":"Fast folding and comparison of RNA secondary structures","volume":"125","author":"Hofacker","year":"1994","journal-title":"Monatsh. Chem."},{"key":"10.1016\/j.ymthe.2026.05.010_bib112","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2044-5040-1-12","article-title":"Establishment of clonal myogenic cell lines from severely affected dystrophic muscles - CDK4 maintains the myogenic population","volume":"1","author":"Stadler","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2026.05.010_bib113","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.3390\/molecules20058304","article-title":"Culture Conditions Affect Expression of DUX4 in FSHD Myoblasts","volume":"20","author":"Pandey","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2026.05.010_bib114","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-1-0716-2772-3_12","article-title":"Knocking down DUX4 in immortalized facioscapulohumeral muscular dystrophy patient-derived muscle cells","volume":"2587","author":"Lim","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2144\/99272bm16","article-title":"Simple mixing device to reproducibly prepare cationic lipid-DNA complexes (lipoplexes)","volume":"27","author":"Hirota","year":"1999","journal-title":"Biotechniques"},{"key":"10.1016\/j.ymthe.2026.05.010_bib116","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-1-0716-2772-3_3","article-title":"Rapid freezing of skeletal and cardiac muscles using isopentane cooled with liquid nitrogen and tragacanth gum for histological, genetic, and protein expression studies","volume":"2587","author":"Anwar","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib118","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/978-1-0716-2772-3_11","article-title":"Morpholino-mediated exons 28-29 skipping of dysferlin and characterization of multiexon-skipped dysferlin using RT-PCR, immunoblotting, and membrane wounding assay","volume":"2587","author":"Anwar","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.05.010_bib117","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/abio.2002.5576","article-title":"Development of an Ultrasensitive Noncompetitive Hybridization\u2013Ligation Enzyme-Linked Immunosorbent Assay for the Determination of Phosphorothioate Oligodeoxynucleotide in Plasma","volume":"304","author":"Yu","year":"2002","journal-title":"Anal. Biochem."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626003977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626003977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:44:57Z","timestamp":1785962697000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626003977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":118,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1525001626003977"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.010","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid nanoparticle delivery of antisense gapmers attenuates pathology in a mouse model of facioscapulohumeral muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}